⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6559458 | 1.00 | — | — | |
| SCHEMBL20901915 | 0.73 | — | — | |
| SCHEMBL193470 | 0.72 | — | — | |
| SCHEMBL28882280 | 0.72 | ALDH1A1 (0.50) | — | |
| SCHEMBL7695480 | 0.69 | ALDH1A1 (0.33) | — | |
| SCHEMBL9411067 | 0.69 | — | — | |
| SCHEMBL1727052 | 0.69 | ALDH1A1 (0.47) | — | |
| SCHEMBL1263638 | 0.69 | ALDH1A1 (0.47) | — | |
| SCHEMBL29894621 | 0.69 | ALDH1A1 (0.47) | — | |
| SCHEMBL15412364 | 0.69 | ALDH1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231194-B1 | FOLATE-IRNA CONJUGATES | ALNYLAM PHARMACEUTICALS INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | BANK OF AMERICA, N.A. | 2015-03-19 | — | — | US | disclosed |
| EP-0731807-B1 | N-2 SUBSTITUTED PURINES | ISIS PHARMACEUTICALS INC (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-1112279-A4 | METHODS FOR THE PREPARATION OF CONJUGATED OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1112279-A1 | METHODS FOR THE PREPARATION OF CONJUGATED OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6232463-B1 | CROSSLINKING OLIGONUCLEOTIDES CONTAINING PURINE ANALOGS HAVING REACTIVE SITES ON THE NUCLEOBASE AND ON A SUGAR MOIETY; ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. | 2001-05-15 | — | — | US | disclosed |
| US-6166199-A | N-2 substituted purines | ISIS PHARMACEUTICALS, INC (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000014098-A1 | METHODS FOR THE PREPARATION OF CONJUGATED OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
| US-5872232-A | 2'-O-modified oligonucleotides | ISIS PHARMACEUTICALS INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5811534-A | PURINE-BASED COMPOUNDS FOR INCLUSION INTO OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-22 | — | — | US | disclosed |
| US-5808027-A | ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-15 | — | — | US | disclosed |
| EP-0742790-A4 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS INC (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5681941-A | GENETIC ENGINEERING; CROSSLINKING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| US-5587469-A | USEFUL AS ?ANTISENSE AGENTS? THAT ARE CAPABLE OF SPECIFIC HYBRIDIZATION WITH A NUCLEOTIDE SEQUENCE OF AN RNA | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-24 | — | — | US | disclosed |
| EP-0742790-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5459255-A | For incorporation into oligonucleotides, cleaving RNA site specifically | ISIS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| WO-1995021184-A1 | SUBSTITUTED PURINES AND OLIGONUCLEOTIDE CROSS-LINKING | ISIS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | disclosed |